CoChat
Sign Up
Cited by 62Hormonal and reproductive studiesGrowth Hormone and Insulin-like Growth FactorsNutrition and Health in Aging

N-Terminal Propeptide of Type III Procollagen as a Biomarker of Anabolic Response to Recombinant Human GH and Testosterone

Open access
Bhasin, Shalender, He, E. Jiaxiu, Kawakubo, Miwa, Schroeder, E. Todd, Yarasheski, Kevin, Opiteck, Gregory J., Reicin, Alise, Chen, Fabian +6 more·2009·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2009-1434PMC PMC2775648
Open this paper in CoChat — free accountOpen PDF

Abstract

CONTEXT: Biomarkers that predict musculoskeletal response to anabolic therapies should expedite drug development. During collagen synthesis in soft lean tissue, N-terminal propeptide of type III procollagen (P3NP) is released into circulation. We investigated P3NP as a biomarker of lean body mass (LBM) and muscle strength gains in response to testosterone and GH. DESIGN: Community-dwelling older men received GnRH agonist plus 5 or 10 g testosterone gel plus 0, 3, or 5 microg recombinant human GH daily. P3NP levels were measured at baseline and wk 4, 8, 12, and 16. LBM and appendicular skeletal muscle mass (ASM) were measured by dual-energy x-ray absorptiometry. RESULTS: One hundred twelve men completed treatment; 106 underwent serum P3NP measurements. P3NP levels were higher at wk 4 than baseline (6.61 +/- 2.14 vs. 4.51 +/- 1.05, P < 0.0001) and reached plateau by wk 4 in men receiving testosterone alone. However, wk 8 P3NP levels were higher than wk 4 levels in men receiving testosterone plus recombinant human GH. Increases in P3NP from baseline to wk 4 and 16 were significantly associated with gains in LBM (r = 0.26, P = 0.007; r = 0.53, P < 0.001) and ASM (r = 0.17, P = 0.07; r = 0.40, P < 0.0001). Importantly, for participants receiving only testosterone, P3NP increases at wk 4 and 16 were related to muscle strength gains (r = 0.20, P = 0.056 and r = 0.36, P = 0.04). In stepwise regression, change in P3NP explained 28 and 30% of the change in ASM and LBM, respectively, whereas change in testosterone but not IGF-I and age provided only small improvements in the models. CONCLUSION: Early changes in serum P3NP levels are associated with subsequent changes in LBM and ASM during testosterone and GH administration. Serum P3NP may be a useful early predictive biomarker of anabolic response to GH and testosterone.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2009-1434

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increase in PIIINP levels is known to be associated with increases in lean body mass and appendicular skeletal mass in the elderly.

    “Increase in PIIINP levels is known to be associated with increases in lean body mass and appendicular skeletal mass in the elderly. 40”

    From A Phase 1 study for safety and pharmacokinetics of BIO101 (20‐hydroxyecdysone) in healthy young and older adults (2023) · cites this paper as [40]

    The Abstract and Discussion report that increases in P3NP were associated with gains in lean body mass and appendicular skeletal muscle mass. The study involved community-dwelling older men receiving testosterone with or without recombinant human GH, so it does not establish the association for elderly people generally. Passage page numbers were not supplied. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Bhasin, S., He, E. J., Kawakubo, M., Schroeder, E. T., Yarasheski, K., Opiteck, G. J., Reicin, A., Chen, F., Lam, R., Tsou, J. A., Castaneda-Sceppa, C., Binder, E. F., Azen, S. P., & Sattler, F. R.
Affiliations
  • Boston University (US)
  • School of Dentistry (E.J.H.), University of Southern California, Los Angeles, California 90089
  • University of Southern California (US)
  • Washington University in St. Louis (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Jean Mayer U.S. Department of Agriculture Human Nutrition Research Center on Aging (C.C.-S.), Tufts University, Boston, Massachusetts 02111
Corresponding author
Bhasin, Shalender
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2009-11-01
Volume
94
Issue
11
Pages
4224-4233
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2009-1434
PMC
PMC2775648
OpenAlex
W1970823846
Cited by
62
References
44
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 9 · 2014: 4 · 2013: 3 · 2012: 5
FWCI
2.19
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Repository Service (Northeastern University) (submittedVersion)
Funders
  • U.S. Department of Agriculture (58-1950-9-001)
  • University of Southern California
  • National Institutes of Health (58-1950-9-001, 5p41rr000954-34, 5P30AG031679, 5p30ag031679-15)
  • Genentech
  • National Institute on Aging (5 P30 AG031679, R01 AG18169, R01AG018169, P30-AG031679, 1R01AG22356)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R21DK074345, R56DK049393, R01DK054163, R01DK049393, P30DK056341)
  • National Center for Research Resources (P41-RR000954, M0I RR000043, M01RR000054, RR000054, M01RR000043, M01RR000036)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
Keywords
recombinant human growth hormone, testosterone, lean body mass, appendicular skeletal muscle mass, muscle strength, older men, GnRH agonist, insulin-like growth factor I, collagen synthesis, sarcopenia prevention, osteoporosis prevention
MeSH terms
Aged, Aged, 80 and over, Body Weight, Hematocrit, Humans, Insulin-Like Growth Factor I, Male, Peptide Fragments, Procollagen, Recombinant Proteins, Regression Analysis, Growth Hormone, Testosterone, Time Factors, Biomarkers, Leuprolide, Human Growth Hormone, Muscle Strength

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review